drugset / Trial / NCT00098384
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Phase 2
Completed
220 enrolled
DuPont, Hurbert L., MD
Bausch Health Americas, Inc. · collabThe University of Texas Health Science Center, Houston · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2003-09
Outcome
Met primary endpoint
paper Rifaximin provided 72% and 77% protection against travelers' diarrhea and antibiotic-treated travelers' diarrhea, respectively (P < 0.001 for both) PMID 15897530 ↗
paper Travelers' diarrhea developed in 14.74% of participants taking rifaximin and 53.70% of those taking placebo PMID 15897530 ↗
Publications
- Background DuPont HL, Jiang ZD, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001 Dec 1;33(11):1807-15. doi: 10.1086/323814. Epub 2001 Oct 23.
- Background DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med. 1993 Jun 24;328(25):1821-7. doi: 10.1056/NEJM199306243282507. No abstract available.
- Results DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005 May 17;142(10):805-12. doi: 10.7326/0003-4819-142-10-200505170-00005.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 200 mg | — |